Evogene EVGN

Evogene targets aGVHD in AI drug program

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Announced aGVHD as target indication
  2. Incorporated by reference in multiple registration statements

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Get an email when Evogene files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2870 and related industry codes: the same peer list as the financial tables.